RESULTS OF DRUG TREATMENT OF PATIENTS WITH METASTASIS OF TRIPLE NEGATIVE BREAST CANCER

Authors

  • Atakhanova N.E Tashkent Medical Academy
  • Almuradova D.M Tashkent Medical Academy
  • Gaziev L.T Tashkent city branch of the Republican
  • Ziyaev Sh.V Tashkent Medical Academy
  • Tashkent city branch of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology
  • Erkinova Ch.O
  • Sadullaeva N.I

Keywords:

triple negative breast cancer, metastases, chemotherapy

Abstract

Breast cancer retains its leading position in terms of the incidence of malignant neoplasms in women. Triple negative breast cancer (TNBC) accounts for 12– 20% of the entire group of breast cancers (BC). TNBC is characterized by the absence of estrogen receptors (ER), progesterone receptors (PR) and HER-2/ neu expression . TNBC is a heterogeneous disease with an aggressive course, with a high risk of early local and distant metastasis to the visceral organs and/or brain. Relapse usually occurs between the 1st and 3rd years, and most patients die within 5 years of the initial diagnosis. Studies have shown that young women predominate among patients with TNBC. Triple negative breast cancer is often associated with BRCA mutations, especially when diagnosed at a young age. Chemotherapy remains the main treatment for patients with TNBC due to the lack of specific drug targets (hormone receptors or HER-2 amplification). However, at present there are no uniform standards for the treatment of patients with TNBC metastases. An important task remains the further study of new regimens and drug regimens for patients with generalized triple-negative breast cancer, which can improve the immediate and long-term results of their treatment.

References

A takhanova , N . E ., Almuradova , D . M ., Khakimov , G . A ., Usmonova , S . T ., & Durmanov , A . S. _ (2020). Values of a mathematical model for predicting the survival of patients with triple negative breast cancer depending on androgen receptors. International Journal of Pharmaceutical Research, 12(3), 695–704. https://doi.org/10.31838/ijpr/2020.12.03.104

Smirmova OV, Borisov VI, Guens GP Immediate and long-term outcomes of drug treatment in patients with metastatic triple negative breast cancer. Malignant Tumors 2018; 3:68–77.

D.M. Almuradova . The role of chemotherapy in triple negative breast cancer. Journal of Drug Delivery and Therapeutics 2018. 8 (5) P.163-167.

Perou CM Molecular stratification of triple-negative breast cancer. J. Oncologist. 2010 Vol. 15(5). P. 39–48.

Carey LA Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA . 2006 Vol . 295.P. _ _ 2492–2502.

Almuradova D.M. Atakhanova N.E. Different chemotherapy regimens in the treatment of metastatic breast cancer with a triple negative phenotype. Journal Bulletin of Science and Practice 2018 No. 3. R. 41-47.

Carey L. _ A. , Dees E. _ C. , Sawyer L. _ et al . The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clinic . Cancer Res. 2007 Vol. 13. P. 2329–2334.

Chavez KJ, Garimella SV, Lipkowitz S. Triple negative breast cancer cell lines : one tool in search for better treatment of triple negative breast cancer. Breast Dis. 2010 Vol. 32(1–2). P. 35–48.

Miller K., Wang M., Gralow J. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New England J. medicine. 2007 Vol. 357 (26). P. 2666–2676.

Miles DW, Chan A., Dirix LY et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clinical Oncology. 2010 Vol. 28 (20). P. 3239–3247.

Linderholm BK, Hellborg H., Johansson U. et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Annals of Oncology. 2009 Vol. 20(10). P. 1639–1646.

Zhang J., Wang L., Wang Z., Hu X., Wang B., Cao J. et al. A phase II trial of biweekly vinorelbine and oxaliplatin in second- or thirdline metastatic triple-negative breast cancer. Cancer biol. Ther. 2015. Vol. 16(2). P. 225–232. DOI: 10.4161/15384047.2014.986973.

Downloads

Published

2023-05-28

Issue

Section

Articles

How to Cite

RESULTS OF DRUG TREATMENT OF PATIENTS WITH METASTASIS OF TRIPLE NEGATIVE BREAST CANCER. (2023). World Bulletin of Public Health, 22, 143-147. https://scholarexpress.net/index.php/wbph/article/view/2804

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>